StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Research analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) in a research note issued to investors on Saturday. The firm set a "hold" rating on the stock.

Tonix Pharmaceuticals Trading Up 17.0 %

TNXP stock traded up $0.06 during midday trading on Friday, hitting $0.38. The company had a trading volume of 182,675,685 shares, compared to its average volume of 67,744,656. The stock has a market cap of $71.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.48. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average price is $0.28 and its 200 day moving average price is $0.28.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, equities research analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.